Neimeth International Pharmaceuticals Plc has announced an impressive 144% surge in post-tax profit for the first half of 2024, reaching N198.2 million. This significant growth is attributed to enhanced production processes and economies of scale.
Key highlights:of shows gross profit soared by 211% to N933.9 million, driven by improved operational efficiency. Turnover increased by 73% to N1.66 billion, indicating robust sales growth.
Cost of sales rose by 10% to N722.8 million, reflecting higher production costs. Marketing and distribution expenses decreased by 42% to N263.9 million, showcasing effective cost management.
Administrative expenses decreased by 10% to N261.7 million, while finance costs nearly doubled to N293.4 million due to higher interest rates and increased borrowings.
The company’s total assets grew to N9.56 billion, while liabilities rose to N7.90 billion. Neimeth is navigating ongoing legal disputes with contingent liabilities of N53 million.
Despite this, the company is focused on strategic expansion, particularly at its Oregun plant in Lagos State, and investing in youth employment initiatives.